Merck KGaA $MRK.DE has taken a major step in expanding its oncology division by acquiring U.S.-based biotech firm SpringWorks Therapeutics, Inc. $SWTX for approximately $3.9 billion. The move is part of the German pharmaceutical giant’s broader strategy to deepen its presence in the rare tumor treatment market, an increasingly competitive segment of the healthcare industry.